Immunocore will announce Q4 2024 financial results on February 26, 2025, followed by a live teleconference. Quiver AI Summary Immunocore Holdings plc announced that it will report its financial ...
Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Investment in March A doctor examining a MRI scan and pointing to an image of a cancerous tumor.
Immunocore Holdings plc (NASDAQ:IMCR) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for IMCR is 53.1.
Immunocore Holdings plc (NASDAQ:IMCR) has a robust pipeline of products currently in the clinical stage including brenetafusp, which is a treatment for melanoma, a type of skin cancer.
Immunocore Holdings plc (NASDAQ:IMCR) shareholders are probably feeling a little disappointed, since its shares fell 4.4% to US$37.20 in the week after its latest second-quarter results. Revenues ...
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune ...
The big shareholder groups in Immunocore Holdings plc (NASDAQ:IMCR) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders ...
Immunocore Holdings plc (NASDAQ: IMCR) Total Value of Insider Purchases In March: $23.99 million Market Capitalization: $1.44 billion Immunocore is a commercial-stage biotechnology company that ...
Immunocore Holdings plc 競合他社・同業他社分析 - Life Sciences セクター
Our AI model demonstrates 73% historical accuracy for IMCR predictions, based on advanced machine learning algorithms trained on over 10 years of market data.